|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2011-2-18
|
|
pubmed:abstractText |
A few reports have assessed HER2 status in breast cancer by both dual-probe fluorescence in situ hybridisation (FISH) and immunohistochemistry (IHC) in an unselected and consecutive fashion, but CEP17 and HER2 copy number were not evaluated separately in these studies. Therefore, the aim of this study was to perform FISH testing for HER2 in a large number of breast tumours, irrespective of the IHC scores, which were also determined in all cases.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1472-4146
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
64
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
200-7
|
|
pubmed:meshHeading |
pubmed-meshheading:21177747-Adult,
pubmed-meshheading:21177747-Aged,
pubmed-meshheading:21177747-Breast Neoplasms,
pubmed-meshheading:21177747-Chromosomes, Human, Pair 17,
pubmed-meshheading:21177747-Female,
pubmed-meshheading:21177747-Gene Dosage,
pubmed-meshheading:21177747-Genes, Neoplasm,
pubmed-meshheading:21177747-Genes, erbB-2,
pubmed-meshheading:21177747-Humans,
pubmed-meshheading:21177747-In Situ Hybridization, Fluorescence,
pubmed-meshheading:21177747-Lymphatic Metastasis,
pubmed-meshheading:21177747-Middle Aged,
pubmed-meshheading:21177747-Neoplasm Proteins,
pubmed-meshheading:21177747-Receptor, erbB-2,
pubmed-meshheading:21177747-Receptors, Estrogen,
pubmed-meshheading:21177747-Receptors, Progesterone
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Relationship between pathological features, HER2 protein expression and HER2 and CEP17 copy number in breast cancer: biological and methodological considerations.
|
|
pubmed:affiliation |
Department of Pathology, University Hospital, Ghent University, De Pintelaan 185, Ghent, Belgium.
|
|
pubmed:publicationType |
Journal Article
|
